- Home
- PRLD vs VNRX Comparison
PRLD vs VNRX Comparison
Compare PRLD & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- VNRX
- Stock Information
- Founded
- PRLD 2016
- VNRX N/A
- Country
- PRLD United States
- VNRX United States
- Employees
- PRLD N/A
- VNRX N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PRLD Health Care
- VNRX Health Care
- Exchange
- PRLD Nasdaq
- VNRX Nasdaq
- Market Cap
- PRLD 73.7M
- VNRX 59.6M
- IPO Year
- PRLD 2020
- VNRX N/A
- Fundamental
- Price
- PRLD $1.05
- VNRX $0.63
- Analyst Decision
- PRLD Strong Buy
- VNRX Strong Buy
- Analyst Count
- PRLD 2
- VNRX 4
- Target Price
- PRLD $4.50
- VNRX $4.17
- AVG Volume (30 Days)
- PRLD 611.2K
- VNRX 154.8K
- Earning Date
- PRLD 02-13-2025
- VNRX 11-14-2024
- Dividend Yield
- PRLD N/A
- VNRX N/A
- EPS Growth
- PRLD N/A
- VNRX N/A
- EPS
- PRLD N/A
- VNRX N/A
- Revenue
- PRLD $3,000,000.00
- VNRX $1,285,827.00
- Revenue This Year
- PRLD N/A
- VNRX $71,446.31
- Revenue Next Year
- PRLD N/A
- VNRX N/A
- P/E Ratio
- PRLD N/A
- VNRX N/A
- Revenue Growth
- PRLD N/A
- VNRX 97.50
- 52 Week Low
- PRLD $0.80
- VNRX $0.43
- 52 Week High
- PRLD $6.80
- VNRX $1.23
- Technical
- Relative Strength Index (RSI)
- PRLD 45.27
- VNRX 48.89
- Support Level
- PRLD $0.98
- VNRX $0.61
- Resistance Level
- PRLD $1.43
- VNRX $0.65
- Average True Range (ATR)
- PRLD 0.12
- VNRX 0.05
- MACD
- PRLD -0.02
- VNRX 0.00
- Stochastic Oscillator
- PRLD 14.14
- VNRX 38.10
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.